Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The PHF6 mRNA 3′UTR is a critical regulatory segment of the messenger RNA encoding the Plant Homeodomain Finger Protein 6 (PHF6). PHF6 is a nucleolar protein that functions as a transcriptional regulator and chromatin remodeler, playing vital roles in neurogenesis and hematopoiesis (UniProt P42704). The 3′UTR contains specific binding sites for microRNAs, most notably miR-128, which post-transcriptionally regulates PHF6 expression levels. Dysregulation of this interaction is a significant factor in the pathogenesis of T-cell acute lymphoblastic leukemia (T-ALL), where PHF6 often functions as a tumor suppressor; its downregulation via the 3′UTR promotes leukemogenesis (Mets et al., 2014, Blood). Additionally, mutations in the PHF6 gene or its regulatory elements are associated with Börjeson-Forssman-Lehmann syndrome, an X-linked intellectual disability disorder. As a therapeutic target, the PHF6 mRNA 3′UTR offers a mechanism to modulate protein abundance using antisense oligonucleotides or miRNA-based therapies, providing a potential pathway for treating hematologic malignancies and certain developmental disorders (Zhang et al., 2013, Nature Neuroscience).
The PHF6 mRNA 3′UTR serves as a binding platform for microRNAs (notably miR-128) and RNA-binding proteins that mediate mRNA degradation or translational repression. Therapeutic strategies involve using miRNA mimics to downregulate PHF6 in contexts where it acts as an oncogene, or using antagomirs/ASOs to block these binding sites and restore PHF6 levels in tumor-suppressor deficient contexts (Mets et al., 2014, Blood; Zhang et al., 2013, Nature Neuroscience).
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Plant homeodomain finger protein 6 mRNA 3′ untranslated region (PHF6 mRNA 3′UTR).